SECURITIES AND EXCHANGE COMMISSION

                            Washington, D.C. 20549

                                   FORM 8-K

                                CURRENT REPORT
                    Pursuant to Section 13 or 15(d) of the
                        Securities Exchange Act of 1934

               Date of Report (Date of Earliest Event Reported):
                     November 13, 2002 (November 8, 2002)

                      ENDO PHARMACEUTICALS HOLDINGS INC.

            (Exact name of registrant as specified in its charter)


    DELAWARE                   39040                         13-4022871
_________________     _________________________           _________________
(State or other        (Commission File Number)            (I.R.S. Employer
jurisdiction of                                           Identification No.)
incorporation)


      100 Painters Drive
      Chadds Ford, Pennsylvania                              19317
________________________________________              _____________________
(Address of principal executive offices)                   (Zip Code)


                                (610) 558-9800
              ___________________________________________________
             (Registrant's telephone number, including area code)


                                      N/A
              ___________________________________________________
         (Former name or former address, if changed since last report)





Item 5.                    Other Events.

         On November 8, 2002, Endo Pharmaceuticals Inc. ("Endo"), a subsidiary
of the Registrant, entered into a Development, Commercialization and Supply
License Agreement (the "License Agreement") with DURECT Corporation
("DURECT"), a copy of which is attached as Exhibit 10.42 to this Report and is
incorporated herein by reference.

         The License Agreement relates to DURECT's development product,
ChronogesicTM (the "Product"). The Product's clinical development program is
on temporary hold pending agreement between DURECT and FDA regarding
additional monitoring and data collection. These protocol changes requested by
the FDA were not in relation to any specific safety issue or adverse event. In
addition, DURECT is currently implementing some necessary design and
manufacturing enhancements to the Product. The changes to the existing
clinical protocol, and the implementation of these design and manufacturing
enhancements, will delay the restart of the development program until the
second half of 2003.

         Under the terms of the agreement, Endo will have no obligation to
fund any of the development costs until the clinical trials are restarted
(which are currently anticipated to begin in the second half of 2003). In the
event that the clinical trials have not restarted by December 31, 2003, then
during the six-month period from January 1, 2004 until the earlier of (a) the
recommencement of the clinical trials and (b) June 30, 2004, Endo will be
responsible for 25% of the development costs actually incurred each month, up
to an aggregate of $3.0 million of development costs for such period.

         Once the Product's clinical trials have restarted or beginning on
June 30, 2004 (whichever is earlier), Endo will be obligated to fund 50% of
the Product's ongoing development costs. Endo will also reimburse DURECT for a
portion of its prior development costs upon the achievement of certain
milestones. Milestone payments made by Endo under the License Agreement could
total up to $52.0 million.

         In addition, under the License Agreement, DURECT licensed to Endo the
exclusive promotional rights to the Product in the U.S. and Canada. Endo will
be responsible for marketing, sales and distribution, including providing
specialty sales representatives dedicated to supplying technical and training
support. DURECT will be responsible for the manufacture of the Product. Endo
and DURECT will share profits equally, based on projected financial
performance of the Product.

         Further, the License Agreement also contains terms and conditions
customary for this type of arrangement, including representations, warranties,
indemnities and termination rights. With respect to termination rights, the
License Agreement permits Endo to terminate its continued participation under
a number of circumstances, one of which could require Endo to pay DURECT $10.0
million.

         Finally, in connection with the License Agreement, Endo will purchase
approximately $5.0 million of newly issued common shares of DURECT,
representing approximately 3% of DURECT's currently outstanding shares.


Item 7.  Financial Statements and Exhibits.

(a)      Financial Statements of Business Acquired.

                  Not applicable.

(b)      Pro Forma Financial Information.

                  Not applicable.

(c)      Exhibits.

Exhibit
Number        Description

10.42         Development, Commercialization and Supply License Agreement,
              dated as of November 8, 2002, by and between DURECT Corporation
              and Endo Pharmaceuticals Inc.*

99.1          Press Release of Endo Pharmaceuticals Holdings Inc. and DURECT
              Corporation dated November 11, 2002


Item 9.  Regulation FD Disclosure.

         On November 11, 2002, the Registrant and DURECT issued a press
release pertaining to the License Agreement, a copy of which is attached as
Exhibit 99.1 to this Report is incorporated herein by reference.

* Confidential portions of this exhibit have been redacted and filed
separately with the Commission pursuant to a confidential treatment request in
accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.


                                  SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.


                            ENDO PHARMACEUTICALS HOLDINGS INC.
                                       (Registrant)


                            By:   /s/ CAROL A. AMMON
                                  Name:  Carol A. Ammon
                                  Title: Chairman & Chief Executive Officer




Dated:  November 13, 2002

<PAGE>

                                                                CONFIDENTIAL



                               INDEX TO EXHIBITS

Exhibit
   No.      Description

10.42       Development, Commercialization and Supply License Agreement,
            dated as of November 8, 2002, by and between DURECT Corporation
            and Endo Pharmaceuticals Inc.*

99.1        Press Release of Endo Pharmaceuticals Holdings Inc. and DURECT
            Corporation dated November 11, 2002

* Confidential portions of this exhibit have been redacted and filed
separately with the Commission pursuant to a confidential treatment request in
accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
[{"type": "8-K", "sequence": "1", "filename": "durect8k.txt", "secsgml_size_bytes": 7004}]
{"company-data": {"conformed-name": "ENDO PHARMACEUTICALS HOLDINGS INC", "cik": "0001100962", "assigned-sic": "2834", "irs-number": "134022871", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-15989", "film-number": "02821083"}, "business-address": {"street1": "223 WILMINGTON-WEST CHESTER PIKE", "city": "CHADDS FORD", "state": "PA", "zip": "19317", "phone": "6105589800"}, "mail-address": {"street1": "223 WILMINGTON-WEST CHESTER PIKE", "city": "CHADDS FORD", "state": "PA", "zip": "19317"}}
SECURITIES AND EXCHANGE COMMISSION

                            Washington, D.C. 20549

                                   FORM 8-K

                                CURRENT REPORT
                    Pursuant to Section 13 or 15(d) of the
                        Securities Exchange Act of 1934

               Date of Report (Date of Earliest Event Reported):
                     November 13, 2002 (November 8, 2002)

                      ENDO PHARMACEUTICALS HOLDINGS INC.

            (Exact name of registrant as specified in its charter)

    DELAWARE                   39040                         13-4022871
_________________     _________________________           _________________
(State or other        (Commission File Number)            (I.R.S. Employer
jurisdiction of                                           Identification No.)
incorporation)

      100 Painters Drive
      Chadds Ford, Pennsylvania                              19317
________________________________________              _____________________
(Address of principal executive offices)                   (Zip Code)

                                (610) 558-9800
              ___________________________________________________
             (Registrant's telephone number, including area code)

                                      N/A
              ___________________________________________________
         (Former name or former address, if changed since last report)

Item 5.                    Other Events.

         On November 8, 2002, Endo Pharmaceuticals Inc. ("Endo"), a subsidiary
of the Registrant, entered into a Development, Commercialization and Supply
License Agreement (the "License Agreement") with DURECT Corporation
("DURECT"), a copy of which is attached as Exhibit 10.42 to this Report and is
incorporated herein by reference.

         The License Agreement relates to DURECT's development product,
ChronogesicTM (the "Product"). The Product's clinical development program is
on temporary hold pending agreement between DURECT and FDA regarding
additional monitoring and data collection. These protocol changes requested by
the FDA were not in relation to any specific safety issue or adverse event. In
addition, DURECT is currently implementing some necessary design and
manufacturing enhancements to the Product. The changes to the existing
clinical protocol, and the implementation of these design and manufacturing
enhancements, will delay the restart of the development program until the
second half of 2003.

         Under the terms of the agreement, Endo will have no obligation to
fund any of the development costs until the clinical trials are restarted
(which are currently anticipated to begin in the second half of 2003). In the
event that the clinical trials have not restarted by December 31, 2003, then
during the six-month period from January 1, 2004 until the earlier of (a) the
recommencement of the clinical trials and (b) June 30, 2004, Endo will be
responsible for 25% of the development costs actually incurred each month, up
to an aggregate of $3.0 million of development costs for such period.

         Once the Product's clinical trials have restarted or beginning on
June 30, 2004 (whichever is earlier), Endo will be obligated to fund 50% of
the Product's ongoing development costs. Endo will also reimburse DURECT for a
portion of its prior development costs upon the achievement of certain
milestones. Milestone payments made by Endo under the License Agreement could
total up to $52.0 million.

         In addition, under the License Agreement, DURECT licensed to Endo the
exclusive promotional rights to the Product in the U.S. and Canada. Endo will
be responsible for marketing, sales and distribution, including providing
specialty sales representatives dedicated to supplying technical and training
support. DURECT will be responsible for the manufacture of the Product. Endo
and DURECT will share profits equally, based on projected financial
performance of the Product.

         Further, the License Agreement also contains terms and conditions
customary for this type of arrangement, including representations, warranties,
indemnities and termination rights. With respect to termination rights, the
License Agreement permits Endo to terminate its continued participation under
a number of circumstances, one of which could require Endo to pay DURECT $10.0
million.

         Finally, in connection with the License Agreement, Endo will purchase
approximately $5.0 million of newly issued common shares of DURECT,
representing approximately 3% of DURECT's currently outstanding shares.

Item 7.  Financial Statements and Exhibits.

(a)      Financial Statements of Business Acquired.

                  Not applicable.

(b)      Pro Forma Financial Information.

                  Not applicable.

(c)      Exhibits.

Exhibit
Number        Description

10.42         Development, Commercialization and Supply License Agreement,
              dated as of November 8, 2002, by and between DURECT Corporation
              and Endo Pharmaceuticals Inc.*

99.1          Press Release of Endo Pharmaceuticals Holdings Inc. and DURECT
              Corporation dated November 11, 2002

Item 9.  Regulation FD Disclosure.

         On November 11, 2002, the Registrant and DURECT issued a press
release pertaining to the License Agreement, a copy of which is attached as
Exhibit 99.1 to this Report is incorporated herein by reference.

* Confidential portions of this exhibit have been redacted and filed
separately with the Commission pursuant to a confidential treatment request in
accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

                                  SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.

                            ENDO PHARMACEUTICALS HOLDINGS INC.
                                       (Registrant)

                            By:   /s/ CAROL A. AMMON
                                  Name:  Carol A. Ammon
                                  Title: Chairman & Chief Executive Officer

Dated:  November 13, 2002
CONFIDENTIAL

                               INDEX TO EXHIBITS

Exhibit
   No.      Description

10.42       Development, Commercialization and Supply License Agreement,
            dated as of November 8, 2002, by and between DURECT Corporation
            and Endo Pharmaceuticals Inc.*

99.1        Press Release of Endo Pharmaceuticals Holdings Inc. and DURECT
            Corporation dated November 11, 2002

* Confidential portions of this exhibit have been redacted and filed
separately with the Commission pursuant to a confidential treatment request in
accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.